SynthesisClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Real-World Effectiveness of RSVpreF and RSVpreF3 Vaccines in Preventing Hospitalization and Emergency Department Visits Associated With Respiratory Syncytial Virus in Older Adults: A Meta-analysis.
Synthesis in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Respiratory syncytial virus disease burden in adults aged ≥50 years old: A retrospective national surveillance database analysis in Mexico (2015-2023).Human vaccines & immunotherapeutics · 2026Article
- An Appraisal of the Potential Downstream Benefits of RSV Vaccination in Older Adults.Reviews in medical virology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) vaccines were first recommended for older adults during the 2023-2024 season in countries that authorized their use. Although early observational studies complemented trial findings, real-world evidence on vaccine effectiveness against severe RSV disease remains limited. We assessed the effectiveness of RSVpreF and RSVpreF3 vaccines in preventing RSV-related hospitalizations and emergency department (ED) visits among older adults.
methodsWe searched MEDLINE, Embase, Web of Science, Scopus, Global Health, and medRxiv for observational studies published between 1 January 2023 and 30 December 2025, reporting real-world effectiveness of RSV vaccines in adults aged 60 years or older. Pooled analyses used inverse-variance random-effects models to estimate effectiveness against RSV-related hospitalizations and ED visits. Subgroup analyses assessed differences in effectiveness by age, immune status, and vaccine type. This study is registered with PROSPERO (CRD420251021777).
resultsFrom 4925 records screened, 8 cohort and case-control studies were included. Vaccination was associated with lower odds of RSV-related hospitalization (odds ratio [OR]: 0.23; 95% confidence interval [CI], 0.20-0.27; I² = 6.5%) and ED visits (OR: 0.23; 95% CI, 0.21-0.27; I² = 0.0%). Effectiveness against RSV-related hospitalization was lower in immunocompromised adults (OR: 0.31; 95% CI, 0.27-0.34; I² = 0.0%) than in immunocompetent individuals (OR: 0.20; 95% CI, 0.11-0.35; I² = 0.0%). Effectiveness did not differ by age group (60-74 vs ≥75 years) or vaccine product.
conclusionsVaccination provided substantial protection against RSV-related healthcare utilization among older adults. Continued surveillance and real-world evidence are needed to inform immunization policy and improve protection in immunocompromised individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.